Osteopenia

From Wikipedia, the free encyclopedia

Template:Short description Template:CS1 config Template:Infobox medical condition (new)

File:Depiction of a woman suffering from Osteopenia.png
Osteopenia exists on a spectrum of normal to dangerously low bone density (osteoporosis).

Osteopenia, also called low bone mass or low bone density, is a condition in which bone density is low.[1] Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop the more serious condition of osteoporosis.[2] In 2010, 43 million older adults in the US had osteopenia.[3] Unlike osteoporosis, osteopenia usually does not cause noticeable symptoms because losing bone density itself does not cause pain.

There is no single cause of osteopenia, although there are several risk factors, including modifiable (behavioral, including dietary and use of certain drugs) and non-modifiable (for instance, loss of bone mass with age). For people with risk factors, measuring bone density using dual-energy X-ray absorptiometry (DXA) can help to measure the development and progression of low bone density.

Prevention of low bone density can begin early in life by eating a healthful diet, doing weight-bearing exercise, minimizing alcoholic beverages, and not smoking tobacco.

The treatment of osteopenia is controversial. Non-pharmaceutical treatment tries to preserve existing bone mass using the above-described healthful behaviors. Pharmaceutical treatment for osteopenia, such as bisphosphonates and other medications, may be considered in certain cases, but that is not without risks. Treatment decisions should be guided by considering the patient's risk factors for fractures.

Risk factors

Many divide risk factors for osteopenia into fixed (non-changeable) and modifiable factors. Osteopenia can also be secondary to other diseases. An incomplete list of risk factors:[4][5][6]

File:615 Age and Bone Mass.jpg
Bone density peaks at 35 and then decreases with age.

Fixed

  • Age: bone density peaks at age 35, and then decreases. Bone density loss occurs in both men and women[7]
  • Ethnicity: European and Asian people have increased risk[8]
  • Sex: women are at higher risk, particularly those with early menopause
  • Family history: low bone mass in the family increases risk

Modifiable / behavioral

  • Tobacco
  • Alcohol
  • Inactivity – particularly lack of weight-bearing or resistance activities[9][10][11]
  • Insufficient caloric intake – osteopenia can be connected to female athlete triad syndrome, which occurs in female athletes as a combination of energy deficiency, menstrual irregularities, and low bone mineral density.[12]
  • Low nutrient diet (particularly calcium, Vitamin D)

Other diseases

  • Celiac disease, via poor absorption of calcium and vitamin D[13][14]
  • Hyperthyroidism[15]
  • Anorexia nervosa[16]

Medications

  • Steroids[17]
  • Anticonvulsants

Screening and diagnosis

The ISCD (International Society for Clinical Densitometry) and the National Osteoporosis Foundation recommend that older adults (women over 65 and men over 70) and adults with risk factors for low bone mass, or previous fragility fractures, undergo DXA testing.[18] The DXA (dual X-ray absorptiometry) scan uses a form of X-ray technology, and offers accurate bone mineral density results with low radiation exposure.[19][20]

The United States Preventive Services Task Force recommends osteoporosis screening for women with increased risk over 65 and states there is insufficient evidence to support screening men.[21] The main purpose of screening is to prevent fractures. Of note, USPSTF screening guidelines are for osteoporosis, not specifically osteopenia.

File:DEXA scanner in use ALSPAC.jpg
A DXA scanner in use.

The National Osteoporosis Foundation recommends use of central (hip and spine) DXA testing for accurate measure of bone density, emphasizing that peripheral or "screening" scanners should not be used to make clinically meaningful diagnoses and that peripheral and central DXA scans cannot be compared to each other.[22]

DXA scanners can be used to diagnose osteopenia or osteoporosis as well as to measure bone density over time as people age or undergo medical treatment or lifestyle changes.[23]

Information from the DXA scanner creates a bone mineral density T-score by comparing a patient's density to the bone density of a healthy young person. Bone density between 1 and 2.5 standard deviations below the reference, or a T-score between −1.0 and −2.5, indicates osteopenia (a T-score smaller than or equal to −2.5 indicates osteoporosis). Calculation of the T-score itself may not be standardized. The ISCD recommends using Caucasian women between 20 and 29 years old as the baseline for bone density for ALL patients, but not all facilities follow this recommendation.[24][25][26][18]

The ISCD recommends that Z-scores, not T-scores, be used to classify bone density in premenopausal women and men under 50.[18]

Prevention

Prevention of low bone density can start early in life by maximizing peak bone density. Once a person loses bone density, the loss is usually irreversible, so preventing (greater than normal) bone loss is important.[27]

Actions to maximize bone density and stabilize loss include:[28][29][30][31]

  • Exercise, particularly weight-bearing exercise, resistance exercises and balance exercises, through mechanical loading that promotes increased bone mass, and reduced fall risk[32]
  • Adequate caloric intake
  • Sufficient calcium in diet: older adults may have increased calcium needs—of note, medical conditions such as Celiac and hyperthyroidism can affect absorption of calcium[29]
  • Sufficient Vitamin D in diet
  • Estrogen replacement
  • Avoidance of steroid medications
  • Limit alcohol use and smoking

Treatment

The pharmaceutical treatment of osteopenia is controversial and more nuanced than well-supported recommendations for improved nutrition and weight-bearing exercise.[33][34][6] The diagnosis of osteopenia in and of itself does not always warrant pharmaceutical treatment.[35][36] Many people with osteopenia may be advised to follow risk prevention measures (as above).

Risk of fracture guides clinical treatment decisions: the World Health Organization (WHO) Fracture Risk Assessment Tool (FRAX) estimates the probability of hip fracture and the probability of a major osteoporotic fracture (MOF), which could occur in a bone other than the hip.[37][38] In addition to bone density (T-score), calculation of the FRAX score involves age, body characteristics, health behaviors, and other medical history.[39]

As of 2014, The National Osteoporosis Foundation (NOF) recommends pharmaceutical treatment for osteopenic postmenopausal women and men over 50 with FRAX hip fracture probability of >3% or FRAX MOF probability >20%.[40] As of 2016, the American Association of Clinical Endocrinologists and the American College of Endocrinology agree.[41] In 2017, the American College of Physicians recommended that clinicians use individual judgment and knowledge of patients' particular risk factors for fractures, as well as patient preferences, to decide whether to pursue pharmaceutical treatment for women with osteopenia over 65.[42]

Pharmaceutical treatment for low bone density includes a range of medications. Commonly used drugs include bisphosphonates (alendronate, risedronate, and ibandronate)—some studies show decreased fracture risk and increased bone density after bisphosphonate treatment for osteopenia.[43] Other medications include selective estrogen receptor modulators (SERMs) (e.g., raloxifene), estrogens (e.g., estradiol), calcitonin, and parathyroid hormone-related protein analogues (e.g., abaloparatide, teriparatide).[44]

These drugs are not without risks.[45][46] In this complex landscape, many argue that clinicians must consider a patient's individual risk of fracture, not simply treat those with osteopenia as equally at risk. A 2005 editorial in the Annals of Internal Medicine states "The objective of using osteoporosis drugs is to prevent fractures. This can be accomplished only by treating patients who are likely to have a fracture, not by simply treating T-scores."[47]

History

Osteopenia, from Greek ὀστέον (ostéon), "bone" and πενία (penía), "poverty", is a condition of sub-normally mineralized bone, usually the result of a rate of bone lysis that exceeds the rate of bone matrix synthesis. See also osteoporosis.

In June 1992, the World Health Organization defined osteopenia.[48][34] An osteoporosis epidemiologist at the Mayo Clinic who participated in setting the criterion in 1992 said "It was just meant to indicate the emergence of a problem", and noted that "It didn't have any particular diagnostic or therapeutic significance. It was just meant to show a huge group who looked like they might be at risk."[49]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."What Is Osteopenia?". familydoctor.org. Retrieved 2021-03-12.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD (September 2007). "Low bone mineral density and fracture burden in postmenopausal women". CMAJ. 177 (6): 575–80. doi:10.1503/cmaj.070234. PMC 1963365. PMID 17846439.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (November 2014). "The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine". Journal of Bone and Mineral Research. 29 (11): 2520–6. doi:10.1002/jbmr.2269. PMC 4757905. PMID 24771492.
  4. ^ Page Module:Citation/CS1/styles.css has no content.staff fo. "What Is Osteopenia? – Osteoporosis". familydoctor.org. Retrieved 2019-12-03.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Who's at risk? | International Osteoporosis Foundation". www.iofbonehealth.org. Retrieved 2019-12-03.
  6. ^ a b Page Module:Citation/CS1/styles.css has no content.Karaguzel G, Holick MF (December 2010). "Diagnosis and treatment of osteopenia". Reviews in Endocrine and Metabolic Disorders. 11 (4): 237–251. doi:10.1007/s11154-010-9154-0. ISSN 1389-9155. PMID 21234807. S2CID 13519685.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Demontiero O, Vidal C, Duque G (April 2012). "Aging and bone loss: new insights for the clinician". Therapeutic Advances in Musculoskeletal Disease. 4 (2): 61–76. doi:10.1177/1759720X11430858. PMC 3383520. PMID 22870496.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Varacallo M, Seaman TJ, Jandu JS, Pizzutillo P (2021), "Osteopenia", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29763053, retrieved 2021-03-12
  9. ^ Page Module:Citation/CS1/styles.css has no content.Duncan CS, Blimkie CJ, Cowell CT, Burke ST, Briody JN, Howman-Giles R (February 2002). "Bone mineral density in adolescent female athletes: relationship to exercise type and muscle strength". Medicine and Science in Sports and Exercise. 34 (2): 286–94. doi:10.1097/00005768-200202000-00017. PMID 11828239.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Kohrt WM, Bloomfield SA, Little KD, Nelson ME, Yingling VR (November 2004). "American College of Sports Medicine Position Stand: physical activity and bone health". Medicine and Science in Sports and Exercise. 36 (11): 1985–96. doi:10.1249/01.mss.0000142662.21767.58. PMID 15514517. S2CID 70468890.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Rector RS, Rogers R, Ruebel M, Hinton PS (February 2008). "Participation in road cycling vs running is associated with lower bone mineral density in men". Metabolism. 57 (2): 226–32. doi:10.1016/j.metabol.2007.09.005. PMID 18191053.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Papanek PE (October 2003). "The female athlete triad: an emerging role for physical therapy". The Journal of Orthopaedic and Sports Physical Therapy. 33 (10): 594–614. doi:10.2519/jospt.2003.33.10.594. PMID 14620789.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Mazure R, Vazquez H, Gonzalez D, Mautalen C, Pedreira S, Boerr L, Bai JC (December 1994). "Bone mineral affection in asymptomatic adult patients with celiac disease". The American Journal of Gastroenterology. 89 (12): 2130–4. PMID 7977227.
  14. ^ Page Module:Citation/CS1/styles.css has no content.Micic D, Rao VL, Semrad CE (July 2019). "Celiac Disease and Its Role in the Development of Metabolic Bone Disease". Journal of Clinical Densitometry. 23 (2): 190–199. doi:10.1016/j.jocd.2019.06.005. PMID 31320223. S2CID 197664092.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Delitala AP, Scuteri A, Doria C (2020-04-06). "Thyroid Hormone Diseases and Osteoporosis". Journal of Clinical Medicine. 9 (4): 1034. doi:10.3390/jcm9041034. ISSN 2077-0383. PMC 7230461. PMID 32268542.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Anorexia Nervosa and Its Impact on Bone Health". Eating Disorders Catalogue. 2018-02-28. Retrieved 2019-12-03.
  17. ^ Page Module:Citation/CS1/styles.css has no content."Glucocorticoid-induced Osteoperosis". www.rheumatology.org. Retrieved 2021-03-12.
  18. ^ a b c Page Module:Citation/CS1/styles.css has no content."2019 ISCD Official Positions – Adult – International Society for Clinical Densitometry (ISCD)". Archived from the original on 2020-10-01. Retrieved 2019-12-03.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Mazess R, Chesnut CH, McClung M, Genant H (July 1992). "Enhanced precision with dual-energy X-ray absorptiometry". Calcified Tissue International. 51 (1): 14–7. doi:10.1007/bf00296209. PMID 1393769. S2CID 33138461.
  20. ^ Page Module:Citation/CS1/styles.css has no content.Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK (January 1999). "Radiation exposure in bone mineral density assessment". Applied Radiation and Isotopes. 50 (1): 215–36. Bibcode:1999AppRI..50..215N. doi:10.1016/s0969-8043(98)00026-8. PMID 10028639.
  21. ^ Page Module:Citation/CS1/styles.css has no content."Final Update Summary: Osteoporosis to Prevent Fractures: Screening – US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. Archived from the original on 2019-12-19. Retrieved 2019-12-03.
  22. ^ Page Module:Citation/CS1/styles.css has no content."Bone Density Test, Osteoporosis Screening & T-score Interpretation". National Osteoporosis Foundation. 17 December 2015. Retrieved 2019-12-03.
  23. ^ Page Module:Citation/CS1/styles.css has no content."Bone Density Scan: MedlinePlus Medical Test". medlineplus.gov. Retrieved 2021-03-12.
  24. ^ Page Module:Citation/CS1/styles.css has no content.Prevention and management of osteoporosis: report of a WHO scientific group. World Health Organization Technical Report Series. Vol. 921. World Health Organization. 2003. pp. 1–164, back cover. hdl:10665/42841. ISBN 978-92-4-120921-2. PMID 15293701.
  25. ^ Page Module:Citation/CS1/styles.css has no content."Fracture Risk Assessment Tool". World Health Organization. Archived from the original on 2009-10-12. Retrieved 2009-09-10.
  26. ^ Page Module:Citation/CS1/styles.css has no content."UpToDate". www.uptodate.com. Retrieved 2019-12-03.
  27. ^ Page Module:Citation/CS1/styles.css has no content."UpToDate". www.uptodate.com. Retrieved 2019-12-03.
  28. ^ Page Module:Citation/CS1/styles.css has no content."Menopause & Osteoporosis". Cleveland Clinic. Retrieved 2019-12-03.
  29. ^ a b Page Module:Citation/CS1/styles.css has no content."Osteoporosis Overview | NIH Osteoporosis and Related Bone Diseases National Resource Center". www.bones.nih.gov. Retrieved 2019-12-03.
  30. ^ Page Module:Citation/CS1/styles.css has no content."Preventing Osteoporosis". International Osteoporosis Foundation. Retrieved 2019-12-03.
  31. ^ Page Module:Citation/CS1/styles.css has no content."Diseases and Conditions Osteoporosis". www.rheumatology.org. Retrieved 2019-12-03.
  32. ^ Page Module:Citation/CS1/styles.css has no content.Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G (2011). "Exercise for preventing and treating osteoporosis in postmenopausal women". The Cochrane Database of Systematic Reviews (7) CD000333. doi:10.1002/14651858.CD000333.pub2. PMID 21735380.
  33. ^ Page Module:Citation/CS1/styles.css has no content.Murphy K (2009-09-07). "New Osteoporosis Diagnostic Tool Draws Criticism". The New York Times. ISSN 0362-4331. Retrieved 2019-12-03.
  34. ^ a b Page Module:Citation/CS1/styles.css has no content."How A Bone Disease Grew To Fit The Prescription". NPR.org. Retrieved 2019-12-08.
  35. ^ Page Module:Citation/CS1/styles.css has no content."One Minute Consult | What is osteopenia, and what should be done about it?". www.clevelandclinicmeded.com. Retrieved 2019-12-08.
  36. ^ Page Module:Citation/CS1/styles.css has no content."Osteopenia Warrants Treatment—Selectively—to Reduce Fracture Risk". EndocrineWeb. Archived from the original on 2021-01-22. Retrieved 2019-12-08.
  37. ^ Page Module:Citation/CS1/styles.css has no content."FRAX — WHO Fracture Risk Assessment Tool". World Health Organization. Retrieved 2010-01-16.
  38. ^ Page Module:Citation/CS1/styles.css has no content.Unnanuntana A, Gladnick BP, Donnelly E, Lane JM (March 2010). "The Assessment of Fracture Risk". The Journal of Bone and Joint Surgery. American Volume. 92 (3): 743–753. doi:10.2106/JBJS.I.00919. ISSN 0021-9355. PMC 2827823. PMID 20194335.
  39. ^ Page Module:Citation/CS1/styles.css has no content."Fracture Risk Assessment Tool". www.sheffield.ac.uk. Retrieved 2019-12-08.
  40. ^ Page Module:Citation/CS1/styles.css has no content.Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (October 2014). "Clinician's Guide to Prevention and Treatment of Osteoporosis". Osteoporosis International. 25 (10): 2359–2381. doi:10.1007/s00198-014-2794-2. ISSN 0937-941X. PMC 4176573. PMID 25182228.
  41. ^ Page Module:Citation/CS1/styles.css has no content.Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R (September 2016). "American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary". Endocrine Practice. 22 (9): 1111–1118. doi:10.4158/EP161435.ESGL. ISSN 1530-891X. PMID 27643923.
  42. ^ Page Module:Citation/CS1/styles.css has no content.Qaseem A, Forciea MA, McLean RM, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians (2017-06-06). "Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians". Annals of Internal Medicine. 166 (11): 818–839. doi:10.7326/M15-1361. ISSN 0003-4819. PMID 28492856.
  43. ^ Page Module:Citation/CS1/styles.css has no content.Iqbal SM, Qamar I, Zhi C, Nida A, Aslam HM (2019-02-27). "Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review". Cureus. 11 (2) e4146. doi:10.7759/cureus.4146. ISSN 2168-8184. PMC 6488345. PMID 31058029.
  44. ^ Page Module:Citation/CS1/styles.css has no content.Rosen CJ (August 2005). "Clinical practice. Postmenopausal osteoporosis". The New England Journal of Medicine. 353 (6): 595–603. doi:10.1056/NEJMcp043801. PMID 16093468.
  45. ^ Page Module:Citation/CS1/styles.css has no content.Editorial Staff (2018-01-30). "Rethinking Drug Treatment for Osteopenia". Health and Wellness Alerts. Archived from the original on 8 December 2019. Retrieved 2019-12-08.
  46. ^ Page Module:Citation/CS1/styles.css has no content.Alonso-Coello P, García-Franco AL, Guyatt G, Moynihan R (January 2008). "Drugs for pre-osteoporosis: prevention or disease mongering?". BMJ. 336 (7636): 126–9. doi:10.1136/bmj.39435.656250.AD. PMC 2206291. PMID 18202066.
  47. ^ Page Module:Citation/CS1/styles.css has no content.McClung MR (2005-05-03). "Osteopenia: To Treat or Not to Treat?". Annals of Internal Medicine. 142 (9): 796–7. doi:10.7326/0003-4819-142-9-200505030-00018. ISSN 0003-4819. PMID 15867413. S2CID 40992917.
  48. ^ Page Module:Citation/CS1/styles.css has no content.says AL (2010-04-12). "What is Osteopenia?". News-Medical.net. Retrieved 2019-12-08.
  49. ^ Page Module:Citation/CS1/styles.css has no content.Kolata G (September 28, 2003). "Bone Diagnosis Gives New Data But No Answers". The New York Times.

Template:Medical resources Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Osteopenia&oldid=1178778"